SkinJect Achieves 80% Response Rate in Phase 2 Trial
Medicus Pharma announced on March 26, 2026, that its lead drug candidate, SkinJect, demonstrated an 80% Overall Response Rate (ORR) in its Phase 2 study. The data from the 200µg dose cohort at day 57 suggests a majority of patients with non-melanoma skin cancer could potentially avoid surgery. This result represents a significant clinical milestone for the company, as it seeks to de-risk the asset and advance toward a registrational pathway with the FDA. The positive data follows the completion of the 90-patient study, which previously reported up to 73% clinical clearance, indicating continued improvement and durability of the treatment's effect.
Company Eyes $8B Market with AI and Pipeline Expansion
To broaden its appeal, Medicus is framing a larger growth story beyond its lead drug. The company is positioning SkinJect for a ~$2 billion market opportunity that includes the rare Gorlin Syndrome. Furthermore, its pipeline includes Teverelix, a treatment for prostate cancer and women's health conditions, which targets an estimated ~$6 billion market. Medicus is also aligning itself with the high-growth artificial intelligence sector through a non-binding collaboration with Reliant AI. By adopting an "agentic AI-driven" drug development plan, the company aims to optimize clinical trials and attract capital from tech-focused investors, tapping into a trend projected to create a $52.6 billion market by 2030.
Financials Reveal $35.4M Loss and 'Going Concern' Warning
Despite the clinical progress, Medicus Pharma's financial health presents a significant risk. The company's annual report for the year ended December 31, 2025, revealed a net loss of $35.4 million, a sharp increase from the $11.2 million loss reported in 2024. With cash and cash equivalents at just $8.7 million against operating expenses of $34.4 million, the company's cash runway is limited. The filing included a critical disclosure from management, stating that "substantial doubt exists regarding the Company’s ability to continue as a going concern without additional financing." This warning underscores the urgent pressure on Medicus to secure new capital or a strategic partner to fund its operations and advance its promising clinical programs.
